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The accumulation of beta amyloid (Ab) has been a primary target for Alzheimer disease therapeutic
strategies. Previously, we discovered an activity from Streptomyces sp. KK565 growth media that
inhibits Ab aggregation. The active component was an aminopeptidase and named Streptomyces
sp. KK565 aminopeptidase (SKAP). SKAP cleaved N-terminal amino-acids of Ab1–42 monomer, inhib-
ited formation of ﬁbrils and protected Ab1–42-induced neurotoxicity. Over-expression of a human
homolog of SKAP, glutamate carboxypeptidase II (hGCPII) in Ab-oversynthesizing cells dramatically
reduced the Ab levels. These ﬁndings suggest a possible role of M28 family peptidases in preventing
Ab deposits in mammalian brain.
Structured summary:
MINT-7992796: SKAP (uniprotkb:Q306T3) physically interacts (MI:0915) with Abeta (uniprotkb:P05067)
by protease assay (MI:0435)
MINT-7992752, MINT-7992778: SKAP (uniprotkb:Q306T3) binds (MI:0407) to Abeta (uniprotkb:P05067)
by protease assay (MI:0435)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction inhibitory activity as an aminopeptidase and named it Streptomy-The progressive accumulation of Ab (beta amyloid) aggregates
is believed to be critical in the initial cellular damage, activating
neuronal cell death and inﬂammation and in the progression of
AD [1,2]. The acceleration of Ab clearance via an amyloid vaccine,
or degradation by enzymatic cleavage holds great promise as ther-
apeutic targets for AD, along with others targeted at reducing Ab
production or blocking Ab ﬁbrillation [3,4]. Soluble Ab is degraded
by several proteases, including neprilysin, insulin-degrading en-
zyme, endothelin-converting enzyme, angiotensin-converting en-
zyme, plasmins, and matrix metalloproteinase-9 [5–10].
In search for a compound that inhibits Ab aggregation, we
screened over 2000 microbial metabolite extracts using Congo
red and thioﬂavin T assays, and isolated an active component from
a water-soluble fraction of a soil microorganism, Streptomyces sp.
KK565 [11]. Here, we have identiﬁed the active Ab aggregationchemical Societies. Published by E
s sp. KK565 aminopeptidase;
naver.com (S.A. Jo).
obiology, College of Medicine,
angwon-Do, 200-702, Repub-ces sp. KK565 aminopeptidase (SKAP).
Aminopeptidases are a family of enzymes that removes amino
acid residues at the N-termini of proteins. Most of the secreted
bacterial aminopeptidases are monomeric and very stable. One of
well-characterized aminopeptidase is Streptomyces griseus amino-
peptidase (SGAP) which belongs to the M28 family of Zn-depen-
dent proteolytic enzymes with co-catalytic metal centers [12,13].
Both amino acid sequence analysis and preliminary biochemical
characterization of SKAP have conﬁrmed that this protein is very
similar to SGAP.
In this study, we demonstrated that the recombinant SKAP pro-
tein in the secreted form (amino acid 39–320) cleaves Ab mono-
mers at the N-terminus and degrades oligomeric and ﬁbrillar
forms as well. Also, SKAP’s inhibitory activity against ﬁbril forma-
tion was conﬁrmed.
2. Materials and methods
2.1. Measurement of enzymatic activity
Aminopeptidase activity was assayed using 1 mM L-leucine
p-nitroanilide (Leu-pNA) as a substrate in 50 mM Tris–HCl buffer,
pH 8.0. The absorbance at 405 nm was measured and the activitylsevier B.V. All rights reserved.
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mM1 cm1 at pH 8). Protein concentration was determined by
Bradford assay using bovine serum albumin as a standard.
2.2. Analysis of Ab cleavage and Ab ﬁbrils
Synthetic Ab1–40 and Ab1–42 were purchased from BioSource or
American Peptide (Sunnyvale, CA). The Ab peptide (50 lM) frag-
ments cleaved by rSKAP were analyzed by assisted laser desorption
ionization time of ﬂight (MALDI-TOF) mass spectroscopy asFig. 1. SKAP belongs to M28 metallopeptidase family and its enzyme activity depends o
mature, secreted form of SKAP (APDIP–TEPPT) used to produce recombinant SKAP
Streptomyces griseus (SGAP), Vibrio proteolyticus (VPAP), Escherichia coli (ECAP), and huma
The amino acid residues reported to be involved in Zn2+-binding (*) and catalysis (**) a
Residues that are conserved in all sequences are highlighted in black and similar ones
dependence of the enzyme activity. The experiments were done in triplicates and the ddescribed in Supplementary methods. The peaks were identiﬁed
by matching their molecular mass from the database using ExPASy
program. Abeta peptides (5 mM in DMSO) were diluted to 0.1 mM
in 10 mM Tris–HCl buffer, pH 8.0 and incubated for 3–7 days at RT
for Ab ﬁbril preparation. For transmission electron microscopy
(TEM), Ab samples were absorbed onto copper grids, stained with
0.5% uranyl acetate, and dried in the dark overnight. The samples
were viewed in an energy ﬁltering TEM (model Leo 912AB; Carl
Zeiss Inc., Wetzlar, Germany; Korea Basic Science Institute–Chun-
cheon, Korea) operated at 120 kV.n Ca2+. (A) The structure and the coding region of SKAP genomic DNA. The putative
(rSKAP) is indicated. (B) Aminopeptidases from Streptomyces sp. KK506 (SKAP),
n glutamate carboxypeptidase II (GCPII) were aligned using CLUSTAL W, version 1.6.
re marked. The numbers on the right indicate the respective amino acid positions.
in gray. (C) Coomassie-stained SDS–PAGE gel of Ni-NTA column fractions. (D) Ca2+
ata are presented as mean ± S.E.M.
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Ab oligomers were prepared according to Dahlgren et al. [14]
and Luibl et al. [15] with minor modiﬁcations. Brieﬂy, Abs were
dissolved in 1,1,1,3,3,3-hexaﬂuoro-2-propanol hexaﬂuoroisopro-
panol (HFIP; Sigma) to a concentration of 1 mM, dried under a
stream of nitrogen gas and stored at 20 C as a HFIP ﬁlm. The
dried peptides were resuspended in DMSO to a concentration of
5 mM, and then diluted to 100 lM in ddH2O. After ﬁltration
through a 0.2 lm ﬁlter, the peptide was incubated at 37 C for
24–48 h to achieve oligomer formation and analyzed using Nu-
PAGE Novex 12% bis–tris polyacrylamide gels (Invitrogen). Abs
were detected by immunoblotting using monoclonal anti-Ab anti-
body (4G8, Cavance).
2.4. Measurement of neuronal cell viability
Human neuroblastoma SH-SY5Y cells were grown in 96-well
plates in DMEM containing 10% fetal bovine serum and 1% penicil-
lin/streptomycin at 37 C/5% CO2. After changing to serum-free
growth media containing N2 supplement (Invitrogen), the cells
were treated with Ab1–42 oligomers. Cell viability was tested by
[3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyltetrazoliumbromide
(MTT; Sigma) assay or 406-diamidino-2-phenylindole (DAPI; Sig-
ma) staining (Supplementary methods).
2.5. Ab aggregation assay
Ab aggregation was measured by Congo red assay as described
previously [11]. Congo red solution (5 lM) prepared in 5 mM
KH2PO4 containing 150 mM NaCl, pH 7.4 was mixed with an Ab
solution and incubated at room temperature for 30 min. The absor-
bance at 480 nm and 540 nm was measured. The amount of CongoFig. 2. MALDI-TOF analysis of Ab products cleaved by rSKAP. Ab1–40 or Ab1–42 peptide
50 mM Tris–HCl buffer, pH 8.0 containing 1 mM CaCl2. The inhibitory effect of 1 mM EDred bound to ﬁbrillar Ab were calculated as Cb (lM) = [(A540 
25 295)  (A480  46 306)]  106.
2.6. Quantitation of Ab peptides by ELISA assay
Amyloid precursor protein with Swedish mutation (APPsw,
K670M671? N670L671) expressing HEK 293 stable cells were trans-
fected with pcDNA3-hGCPII plasmid DNA cloned from human
astrocytes (Supplementary methods). The vector (pcDNA3) was
transfected as a negative control. The media was changed after
24 h and incubated for 8 h. The culture media were collected and
assayed for Ab1–40 or Ab1–42 using ELISA kits (Biosource).3. Results
3.1. Cloning of SKAP gene and production of recombinant SKAP
From the culture broth of Streptomyces sp. KK565, the Ab aggre-
gation inhibitory activity was puriﬁed by several puriﬁcation steps
(Supplementary methods). Based on the N-terminal amino acid se-
quence (-APDIP) of puriﬁed protein with apparent molecular
weight of 30 kDa, a 1405-bp DNA covering the full-length SKAP
coding region was cloned by inverse PCR. One open reading frame
of 1314 bp encoding a 437 amino acid protein with an estimated
molecular mass of 45 kDa was identiﬁed (Fig. 1A). This premature
form is likely to be processed further to a 30 kDa mature secreted
form (amino acid 39–320). The core region of SKAP has high amino
acid sequence homology: 85.9% identity to SGAP (P80561 and
AB125217, NCBI) and 29.8% to glutamate carboxypeptidase II
(hGCPII) (NM_001014986, NCBI). Sequence alignment revealed
the conservation of the key amino acids involved in the catalytic
activity and Zn-binding among peptidases (Fig. 1B) [16,17].(50 lM) was incubated with 0.36 units of puriﬁed rSKAP (C–F) at 37 C for 3 h in
TA was tested (E and F). Each peak is labeled with amino acid numbers of Ab.
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320) was prepared as described in Supplementary methods. The
one-step puriﬁcation using Ni-NTA column yielded a 45.6% recov-
ery from the culture medium and a 56-fold enrichment of the
speciﬁc activity. The apparent molecular weight of the puriﬁed
rSKAP was approximately 30 kDa on a SDS–PAGE gel (Fig. 1C). Re-
combinant SKAP was recognized by anti-His6-tag antibody. The
aminopeptidase activity was increased approximately 2.3-fold in
the presence of 1 mM Ca2+ and inhibited almost completely by
Ca2+ chelators, EDTA or EGTA (Fig. 1D). A metallopeptidase inhib-
itor, p-phenanthroline, also inhibited the enzymatic activity by
50% at 10 lM and completely at 100 lM. The optimal pH for
SKAP activity was around pH 8 in the presence of 1 mM CaCl2
(data not shown).
3.2. Ab cleavage by puriﬁed recombinant SKAP
We speculated that the inhibition of Ab aggregation by SKAP is
due to the cleavage of Ab by SKAP based on its aminopeptidaseFig. 3. Degradation of Ab oligomers and ﬁbrils by rSKAP. Ab1–42 oligomers (25 lM prepa
37 C in the presence or absence of 1 mM CaCl2 and run on a Nu-PAGE 12% polyacryla
antibody (4G8). The low-molecular weight bands from another blot are shown in (B). M
cells were treated for 24 h at 37 C with Ab1–42 oligomers (5 lM) preincubated with rSK
media (0.02 units) or rSKAP (0.18 units) for 3 days at 37 C. The amount of Ab ﬁbrils was m
Ab1–42 ﬁbrils incubated with either rSKAP (0.72 units) or buffer for 6 days at 37 C w
disappearance of ﬁbrillar structure.activity. The puriﬁed rSKAP was incubated with either Ab1–40 or
Ab1–42 peptide and the cleaved products were analyzed using MAL-
DI-TOF (Fig. 2). From the Ab1–40 peptide, 2–40, 3–40, 5–40, 6–40,
and 7–40 peptide fragments were generated, indicating that the
N-terminal amino acid (Asp) through the sixth amino acid (His)
were cleaved consecutively, except the third amino acid (Glu)
(Fig. 2C). Prolonged incubation with the enzyme for up to 48 h
cleaved the N-terminus further, but not beyond the eleventh ami-
no acid. The cleavage pattern for Ab1–42 was quite similar to that of
Ab1–40 (Fig. 2D). Cleavage of both Ab1–40 and Ab1–42 by SKAP were
completely blocked by EDTA and no cleaved product of Ab was de-
tected (Fig. 2E and F).
To test the substrate speciﬁcity of SKAP, the digestion products
of amylin and several neuropeptides were analyzed by MALDI-TOF.
SKAP cleaved only the ﬁrst N-terminal amino acid of amylin and b-
endorphin and several sites at the N-terminus of somatostatin and
vasoactive intestinal peptide. But no cleavage product of Ab40–1 re-
verse peptide and neuropeptide Y was detected (data not shown).
Thus these results showed some substrate selectivity.red as described in Supplementary methods) were incubated with rSKAP for 6 h at
mide gel. (A) Immunoblot analysis of Ab1–42 oligomers using monoclonal anti-Ab
easurement of cell viability using the MTT assay (C) and DAPI staining (D). SH-SY5Y
AP for 24 h at 37 C. (E) Ab1–42 ﬁbrils (50 lM) were incubated with KK565 culture
easured using Congo red assay. *P = 0.074 for KK565 media; **P < 0.01 for rSKAP. (F)
ere visualized by Electron microscopy. Scale bar = 500 nm. Arrows indicate the
Fig. 4. Overexpression of human GCPII, a mammalian homologue of SKAP reduces
the extracellular Ab level. (A) HEK293 cells stably expressing APP Swedish mutant
were transfected with pcDNA3-hGCPII or control vector. After 24 h the culture
media was changed and incubated for 8 h. Then, the amount of Ab1–40 or Ab1–42 in
the media was measured using an Elisa assay kit (Biosource). (B) The culture media
and cell lysate used in experiment (A) were immunoblotted for sAPP and GCPII,
respectively.
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neurotoxicity
To determine whether SKAP can degrade soluble Ab oligomers,
Ab1–42 oligomers treated with rSKAP for 6 hr were analyzed by
western blotting (Fig. 3A). The 50–100 kDa oligomeric forms were
clearly decreased by rSKAP, as well as trimers and dimers in an en-
zyme concentration-dependent manner (0.07–0.36 unit). In addi-
tion, at a high rSKAP concentration (3.6 unit), the cleaved
monomer band was detected (Fig. 3B). Therefore, SKAP is likely
to degrade efﬁciently the preformed Ab1–42 multimers.
Next, we tested the effect of the enzyme on Ab-induced toxicity.
When SH-SY5Y cells were treated Ab1–42 oligomers, the cell viabil-
ity was decreased by 25% measured by MTT assay (Fig. 3C). How-
ever, preincubation of Ab1–42 oligomers with rSKAP recovered the
cell viability signiﬁcantly to 89%. Recombinant SKAP alone caused
no damage to cells. Similar protective effects of SKAP were ob-
served by DAPI staining. The number of apoptotic cells with the
condensed chromatin or fragmented nuclear bodies were in-
creased in Ab1–42 treated cells but decreased upon pre-incubation
with rSKAP (Fig. 3D, arrows). These results suggested that SKAP
protects cells from Ab1–42 -induced cell death by cleaving Ab1–42
into small fragments which do not cause neurotoxicity.
3.4. SKAP blocks Ab ﬁbril formation
We also examined the effects of SKAP on Ab ﬁbril formation.
The culture media of Streptomyces sp. KK565 reduced Ab ﬁbrils
by 20% and puriﬁed rSKAP by 37% (Fig. 3E). This SKAP-mediated
reduction of Ab1–42 ﬁbril formation was time-dependent up to
7 days of incubation (data not shown). Similar activity of SKAP
was observed with ﬁbrils of Ab1–40 (data not shown). The effect
of SKAP on pre-formed Ab ﬁbril was conﬁrmed by ultrastructural
changes of Ab1–42 ﬁbrils examined by negative TEM staining
(Fig. 3F). TEM showed long, thin Ab ﬁbrils of approximately
10 nm in diameter and some thicker aggregates of ﬁbrils were ob-
served. The incubation with rSKAP induced a marked decrease in
the amount of ﬁbrillar structures, and instead, amorphous struc-
tures suggestive of decomposed ﬁbrils were observed.
3.5. Overexpression of human GCPII enhances the clearance of
extracellular Abs
In order to investigate physiological relevance of SKAP, we
examined if hGCPII, a human SKAP homolog, also cleaves Ab or en-
hances its clearance. We found that GCPII cleaves both Ab40 and
Ab42. We also tested overexpression effect of hGCPII on Ab clear-
ance by transfecting hGCPII cDNA into HEK293 cells stably
expressing APPsw. As shown in Fig. 4A, the concentration of Abs
in the media of hGCPII-transfected cells was almost half (53.5%
for Ab1–40, 56.5% for Ab1–40) of the vector control cells. Since the
levels of soluble APP (sAPP) in the media of these cells were similar
(Fig. 4B), no effect on APP processing by hGCPII overexpression.4. Discussion
One way to prevent the pathogenesis of AD is to block the
aggregation of Ab peptides. Here, we identiﬁed the strong Ab
aggregation inhibitory activity in microbial metabolic extract of
Streptomyces sp. KK565 [11] as an aminopeptidase. Because the
mature SKAP is secreted into the media, we puriﬁed rSKAP from
the bacterial culture media instead of the extract, from which we
could barely gain the native protein due to its propensity to
aggregate.Since SKAP is a new aminopeptidase similar to SGAP which be-
longs to the M28 family of metallopeptidases, we hypothesized
that its inhibitory activity against Ab aggregation is due to proteo-
lytic cleavage of Ab. As evidenced by the MALDI-TOF analysis, SKAP
cleaves both Ab1–40 and Ab1–42 at the N-terminal position, produc-
ing the various N-terminally cleaved products, Abx–40,42. No endop-
eptidyl and C-terminal cleaved Ab products were detected,
suggesting a unique property of aminopeptidase. SKAP is likely to
cleave Ab1–40 and Ab1–42 peptides from the ﬁrst (D) up to tenth
(Y) amino acid successively. However, some intermediate products
(4–40/42, 9–40/42, and 10–40/42) were not detected, and we as-
sume that these fragments are hydrolyzed quickly.
How the N-terminal cleavage contributes to the reduction of Ab
oligomerization is not clear. Generally, the hydrophobic parts, cen-
ter to the C-terminus of the full-length Ab are considered the driv-
ing force to form amyloid deposition in vitro [18]. The N-terminal
His-6 and Asp-7 have been proposed as the Cu (II)-binding site, and
this metal–His interaction facilitates the intermolecular contacts at
the hydrophobic regions of Ab [19]. Thus, the N-terminus may also
play a crucial role in peptide aggregation. With regard to the role of
N-terminus in Ab aggregation, aminopeptidase A, a membrane-
bound Zn-metalloprotease, has been reported to cleave Ab at the
N-terminus and modify staurosporine-stimulated caspase-3 activ-
ity [20]. Although we are not certain whether the cleaved product
(Ab2–42) is more toxic than Ab1–42, the possibility exists that Ab2–42
is further degraded by other proteases such as a mammalian
homolog of SKAP. Since Ab11–40 and Ab11–42, the major cleaved
products by SKAP, lose aggregation property and are much less
toxic to neuronal cells (Supplementary Fig.) the consequence of
SKAP-mediated enzymatic action toward Abs is likely the protec-
tion of neuronal cells by producing the products which are less
prone to aggregate.
Our observation that SKAP not only reduced the formation of
the Congo red-positive aggregates [11], but dissolved the pre-
formed Ab1–42 oligomers and ﬁbrils (Fig. 3), suggest a potential,
critical role of the M28 family peptidases in stimulating amyloid
clearance in human brain. This physiological relevance was further
suggested by a fact that GCPII, a human homolog of SKAP showed
an Ab-degrading activity and played a physiological role in clear-
ance of Ab peptides in the brains of AD model mice (Fig. 4 and
Kim et al. [21]). Taken together, our results demonstrated, for the
ﬁrst time, the implication of the M28 family aminopeptidase in
amyloid peptide catabolism in the brain.
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